Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica

(2012) Ingo Kleiter   ARCHIVES OF NEUROLOGY

Therapeutic Targeting of the Interleukin-6 Receptor

(2011) Toshio Tanaka et al.   Annual Review of Pharmacology and Toxicology

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder

(2011) Ju-Hong Min et al.   Multiple Sclerosis Journal

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica

(2011) Norio Chihara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice

(2010) Samira Saadoun et al.   BRAIN

IFN -1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum

(2010) J. Shimizu et al.   NEUROLOGY

Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo

(2009) Monika Bradl et al.   ANNALS OF NEUROLOGY

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

Review: Treatment of neuromyelitis optica: Current debate

(2008) Tomoko Okamoto et al.   Therapeutic Advances in Neurological Disorders